There is basically no research that looks at the impact of antidepressants on emerging sexuality. Here are the key things we ...

A new malaria drug, Ganaplacide/Lumefantrine, shows over 97% cure rates in trials. This treatment is effective even where ...

Have you ever wondered how scientists test new medicines before they reach people? The process must be safe, accurate, and ...

Denmark's Zealand Pharma said on Thursday it has paused the development of an early-stage obesity drug candidate as it shifts focus to more promising programs. The drug dapiglutide, a GLP-1/GLP-2 ...

The decision to pause dapiglutide will help Zealand focus investment into assets that have “the greatest potential for ...

With an AI-led platform for drug discovery and a growing global client base, Medvolt AI is emerging as one of India’s most ...

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Repligen (NASDAQ:RGEN) and its peers.

Editor's note: this interview was originally published on BioPharmInternational.com.

AI drives decision inputs: In 2025, both big pharma and small pharma use advanced predictive modeling, digital twins, and AI-powered analytics throughout R&D and regulatory processes. This reduces ...

Technical insights session to highlight human-in-the-loop AI agent workflows in drug development. GAITHERSBURG, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. ( ...

OneSource Specialty Pharma has raised its FY28 revenue forecast from $400 million to over $500 million, driven by strong ...

Abzena and Mabqi have announced a partnership integrating antibody discovery capabilities with development and manufacturing ...